Using 68Ga-FAPI PET/CT to find thyroid cancer recurrence after surgery
The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery
This study is testing if a special type of scan can help find thyroid cancer that has come back after surgery in patients who are at risk for recurrence.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Ruijin Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06800768 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 68Ga-FAPI PET/CT imaging in detecting recurrent and metastatic lesions in patients who have undergone surgery for thyroid cancer. Participants will be numbered and their medical history, including age and gender, will be recorded. When recurrence or metastasis is suspected, they will undergo a 68Ga-FAPI PET/CT scan, and the results will be compared to follow-up findings or histopathological results to assess accuracy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-80 who have had surgery for thyroid cancer and are suspected of having recurrence or metastasis.
Not a fit: Patients with serious comorbidities or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the detection of recurrent thyroid cancer, leading to timely and potentially life-saving interventions.
How similar studies have performed: While the use of PET/CT imaging in cancer detection is established, the specific application of 68Ga-FAPI in thyroid cancer is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with thyroid cancer who have undergone surgery and are suspected of recurrence or metastasis during clinical evaluation. 2. Signed and dated informed consent form. 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. Aged 18-80 years old. Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction. 3. Pregnant women and women who may be pregnant, women who are breastfeeding. 4. Non-compliant person.
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (Recruiting)
Study contacts
- Study coordinator: Jiajia Hu
- Email: jiajiahu@shsmu.edu.cn
- Phone: 13524945287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.